aod9604 phase 2 trial results weight loss kg or percent AOD-9604 Dosage Guide: Complete Protocol for Safe Administration AOD 9604 vs tirzepatide: which
Description
Regulatory watch Last reviewed Jul 1, 2026 Next review Jul 29, 2026 Evidence snapshot AOD-9604 was developed by Metabolic Pharmaceuticals (Australia) as a modified C-terminal fragment (residues 177-191) of human growth hormone, designed to retain lipolytic activity without growth-promoting effects
This is an important caveat
Education is also a key part of our process
Lyophilized (unreconstituted): Stable at room temperature for several weeks
